Skip to content

G&A at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
$13.98M-0.7%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$14.61M+25.4%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$50.83M+43.1%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$23.82M+25.1%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$19.38M+43.5%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$28.24M+137%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s G&A?
MBX Biosciences, Inc. (MBX) reported G&A of $8.79M in Q1 2026.
How has MBX Biosciences, Inc.'s G&A changed year-over-year?
MBX Biosciences, Inc.'s G&A increased by 113.2% year-over-year, from $4.12M to $8.79M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.